Cartesian Therapeutics, Inc. announced the appointment of Kemal Malik, MBBS to its Board of Directors. Dr. Malik brings to Cartesian over 30 years of global development, regulatory, and commercial expertise at leading pharmaceutical organizations. Dr. Malik spent nearly 25 years in key leadership positions at Bayer, where he served for ten years as Head of Global Development and Chief Medical Officer, leading the company?s clinical development and regulatory functions, notably overseeing twenty consecutive positive Phase 3 trials and the approval of several blockbuster drugs across multiple therapeutic areas.

Prior to this role, he served as Head of the Global Medical organization. Dr. Malik began his career at Bristol-Myers Squibb where he held various roles focused on medical affairs, clinical development, and new product commercialization. Following his role as Head of Development, Dr. Malik was appointed to the Executive Board of Management of Bayer where he was responsible for driving innovation across the Bayer group.

In this role, he established Bayer LEAPS, a business unit responsible for strategic innovative medicines, including cell and gene therapies and mRNA technology. Dr. Malik currently serves as a Board member of Syncona, a scientific advisor for Atomwise, and a member of the Board of Trustees for Future Health. He previously served on the Board of Directors of Acceleron Pharma.

Dr. Malik studied at the Imperial College School of Medicine in London receiving a B.Sc. in Pharmacology and graduating with MBBS. He is a member of the Royal College of Physicians.